Use of Exenatide and Pramlintide to Decrease Post-prandial Hyperglycemia
NCT01269047 on ClinicalTrials.gov · last registry update 2018-04-12
A small phase 4 — 37 participants, against a typical 75. Completed August 2016. exenatide is approved in the US, but not for type 1 diabetes — a registration here is not an approval, and most drugs tested in a new condition never get one for it.
- Status
- COMPLETED
- Phase
- P4
- Drug
- exenatideBydureon, Byetta
- Sponsor
- Albert Einstein College of Medicine
- Sponsor type
- Other
- Enrollment
- 37
- Started
- 2009-08
- Primary completion
- 2016-08 actual
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
Post-prandial Blood Glucose Concentration in Both Pramlintide and Exenatide Treated Groups in Acute and Chronic Setting, Compared to Insulin Monotherapy in Type 1 Diabetes Mellitus.
Conditions studied
Type 1 Diabetes
Every field above is taken directly from the registry record. See all detected changes across the class, or the exenatide page for this molecule’s full trial and approval history.